DK1427411T3 - -(-)-1-(3,4-dichlorphenyl)-3-azabicyclo[3.1.0]hexan, præparater deraf og anvendelser som dopamingenoptagelsesinhibitor - Google Patents

-(-)-1-(3,4-dichlorphenyl)-3-azabicyclo[3.1.0]hexan, præparater deraf og anvendelser som dopamingenoptagelsesinhibitor

Info

Publication number
DK1427411T3
DK1427411T3 DK02796380T DK02796380T DK1427411T3 DK 1427411 T3 DK1427411 T3 DK 1427411T3 DK 02796380 T DK02796380 T DK 02796380T DK 02796380 T DK02796380 T DK 02796380T DK 1427411 T3 DK1427411 T3 DK 1427411T3
Authority
DK
Denmark
Prior art keywords
azabicyclo
dichlorophenyl
hexane
preparations
uptake inhibitor
Prior art date
Application number
DK02796380T
Other languages
Danish (da)
English (en)
Inventor
Arnold Stan Lippa
Joseph Williams Epstein
Original Assignee
Dov Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dov Pharmaceutical Inc filed Critical Dov Pharmaceutical Inc
Application granted granted Critical
Publication of DK1427411T3 publication Critical patent/DK1427411T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
DK02796380T 2001-08-24 2002-08-14 -(-)-1-(3,4-dichlorphenyl)-3-azabicyclo[3.1.0]hexan, præparater deraf og anvendelser som dopamingenoptagelsesinhibitor DK1427411T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/939,071 US6569887B2 (en) 2001-08-24 2001-08-24 (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
PCT/US2002/025870 WO2003017927A2 (en) 2001-08-24 2002-08-14 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor

Publications (1)

Publication Number Publication Date
DK1427411T3 true DK1427411T3 (da) 2007-07-02

Family

ID=25472498

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02796380T DK1427411T3 (da) 2001-08-24 2002-08-14 -(-)-1-(3,4-dichlorphenyl)-3-azabicyclo[3.1.0]hexan, præparater deraf og anvendelser som dopamingenoptagelsesinhibitor

Country Status (21)

Country Link
US (6) US6569887B2 (zh)
EP (1) EP1427411B1 (zh)
JP (1) JP2005504049A (zh)
KR (1) KR20040065549A (zh)
CN (2) CN101050199A (zh)
AT (1) ATE355838T1 (zh)
BR (1) BR0212147A (zh)
CA (1) CA2458217A1 (zh)
DE (1) DE60218703T2 (zh)
DK (1) DK1427411T3 (zh)
ES (1) ES2284968T3 (zh)
HU (1) HUP0401515A2 (zh)
IL (1) IL160545A0 (zh)
MX (1) MXPA04001643A (zh)
NO (1) NO327424B1 (zh)
NZ (1) NZ531606A (zh)
PL (1) PL368601A1 (zh)
PT (1) PT1427411E (zh)
RU (1) RU2300522C2 (zh)
WO (1) WO2003017927A2 (zh)
ZA (1) ZA200401545B (zh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US20060173064A1 (en) * 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
US20060287283A1 (en) * 2003-07-09 2006-12-21 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
PT2060570E (pt) * 2004-02-23 2012-05-07 Glaxo Group Ltd Derivados de azabiciclo(3.1.0)-hexano úteis como moduladores dos receptores d3 da dopamina
US20050282859A1 (en) * 2004-06-04 2005-12-22 Thor Karl B Dual acting SNRI-NMDA antagonists for the treatment of genitourinary disorders
US20060020014A1 (en) * 2004-07-22 2006-01-26 Wyeth Method for treating nervous system disorders and conditions
MX2007000853A (es) * 2004-07-22 2007-03-26 Wyeth Corp Procedimiento para el tratamiento de trastornos y dolencias del sistema nervioso.
KR20070045278A (ko) * 2004-07-22 2007-05-02 와이어쓰 신경계 질환 및 장애의 치료 방법
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
US20060100263A1 (en) * 2004-11-05 2006-05-11 Anthony Basile Antipyretic compositions and methods
US20060217394A1 (en) * 2005-02-23 2006-09-28 Silvan S. Tomkins Institute, Inc. Treatment of anhedonia
US20110015246A2 (en) * 2005-03-14 2011-01-20 Agean Llc Lofexidine enantiomers for use as a treatment for cns disease and pathologies and its chiral synthesis
WO2006107019A1 (ja) * 2005-04-04 2006-10-12 Takeda Pharmaceutical Company Limited うつ病または不安神経症の予防または治療剤
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
JP2009502798A (ja) * 2005-07-21 2009-01-29 ワイス 神経系障害および状態の処置方法
KR20170005888A (ko) 2005-07-27 2017-01-16 뉴로반스, 인크. 신규 1-아릴-3-아자바이사이클로［3.1.0］헥산：제조 방법 및 신경 정신 질환 치료를 위한 용도
US20080045725A1 (en) 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
US20070297991A1 (en) * 2006-06-23 2007-12-27 Minu, L.L.C. Neural conduit agent dissemination for smoking cessation and other applications
US7691893B2 (en) * 2006-09-11 2010-04-06 Glaxo Group Limited Chemical compounds
US20080269348A1 (en) * 2006-11-07 2008-10-30 Phil Skolnick Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use
US8138377B2 (en) * 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
GB0625198D0 (en) 2006-12-18 2007-01-24 Glaxo Group Ltd Chemical compounds
ATE513808T1 (de) * 2006-12-19 2011-07-15 Hoffmann La Roche Heteroarylpyrrolidinyl- und piperidinylketonderivate
NZ581391A (en) * 2007-04-30 2012-06-29 Adolor Corp Compositions of (-)-e-10-oh-nt and methods for their synthesis and use
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
WO2008153937A2 (en) * 2007-06-06 2008-12-18 Dov Pharmaceutical, Inc. Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
BRPI0914160A2 (pt) 2008-06-18 2019-09-24 Hoffmann La Roche aril cetona como mri
CN102803224A (zh) 2009-06-26 2012-11-28 万能药生物有限公司 新的氮杂双环己烷类化合物
CN102417475A (zh) * 2010-09-28 2012-04-18 江苏恒瑞医药股份有限公司 氮杂双环辛烷类衍生物、其制备方法及其在医药上的应用
WO2013019271A1 (en) * 2011-07-30 2013-02-07 Neurovance, Inc. Use of (1r,5s)-(+)-1-(naphthalen-2-yl)-3-azabicyclo{3.1.0}hexane in the treatment of conditions affected by monoamine neurotransmitters
US20130123238A1 (en) * 2011-11-16 2013-05-16 Anthony Alexander McKINNEY Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane to treat addictive and alcohol-related disorders
US9566264B2 (en) 2013-07-01 2017-02-14 Euthymics Bioscience, Inc. Combinations and methods
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US411839A (en) * 1889-10-01 Machine for grinding and polishing road scraper blades
BE800903A (fr) * 1973-06-14 1973-12-14 Babitsky Boris D Procede d'obtention de polymeres d'alcoyl-2 butadienes-1,3 ou de copolymeres d'alcoyl-2 butadienes-1,3-butadiene-1,3
US3892772A (en) 1973-12-04 1975-07-01 American Cyanamid Co Isomer of 1-(p-chlorophenyl)-1,2-cyclopropanedicarboximide and method of use
JPS535994B2 (zh) 1974-09-26 1978-03-03
US4131611A (en) 1975-07-31 1978-12-26 American Cyanamid Company Azabicyclohexanes
US4231935A (en) 1975-07-31 1980-11-04 American Cyanamid Company 1-Phenyl-3-azabicyclo[3.1.0]hexanes
US4196120A (en) 1975-07-31 1980-04-01 American Cyanamid Company Azabicyclohexanes, method of use and preparation of the same
US4088652A (en) 1975-07-31 1978-05-09 American Cyanamid Company Acylazabicyclohexanes
GB1532682A (en) * 1976-04-27 1978-11-22 Bristol Myers Co Process for the preparation of cephadroxil
GR72713B (zh) 1976-09-15 1983-12-01 American Cyanamid Co
US4118393A (en) 1977-06-23 1978-10-03 American Cyanamid Company Phenyl azabicyclohexanones
US4118417A (en) 1977-06-23 1978-10-03 American Cyanamid Company Process for resolving cis-1-substituted phenyl-1,2-cyclopropanedicarboxylic acids
IL65843A (en) 1977-08-11 1986-12-31 American Cyanamid Co Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type
CH644580A5 (de) 1980-01-29 1984-08-15 Hoffmann La Roche Cyclohexen-derivate.
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4435419A (en) 1981-07-01 1984-03-06 American Cyanamid Company Method of treating depression using azabicyclohexanes
DE3324263A1 (de) 1983-07-06 1985-01-17 Hoechst Ag, 6230 Frankfurt Derivate der 2-azabicyclo(3.1.0)hexan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie 2-azabicyclo(3.1.0)hexan-derivate als zwischenprodukte und verfahren zu deren herstellung
US5316759A (en) 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
DE3822792C2 (de) 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
US5198459A (en) 1987-07-11 1993-03-30 Sandoz Ltd. Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
US5130430A (en) 1990-10-31 1992-07-14 Neurogen Corporation 2-substituted imidazoquinoxaline diones, a new class of gaba brain receptor ligands
US6204284B1 (en) 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US5232934A (en) 1992-07-17 1993-08-03 Warner-Lambert Co. Method for the treatment of psychomotor stimulant addiction
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
WO1995001175A1 (en) * 1993-07-02 1995-01-12 The University Of Nottingham Immunosuppressant and antiallergic compounds, e.g. n-(3-oxohexanoyl) homoserine lactone
US5556837A (en) 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
US5488056A (en) 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
US5762925A (en) 1994-11-03 1998-06-09 Sagen; Jacqueline Preventing opiate tolerance by cellular implantation
ES2167587T3 (es) * 1995-07-17 2002-05-16 Warner Lambert Co Forma cristalina de la sal hemicalcica del acido (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (atorvastatina).
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
TW513409B (en) 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
US5911992A (en) 1997-06-12 1999-06-15 A. Glenn Braswell Method for controlling weight with hypericum perforatum and garcinia cambogia
US6121261A (en) 1997-11-19 2000-09-19 Merck & Co., Inc. Method for treating attention deficit disorder
PT1048653E (pt) 1997-12-05 2004-07-30 Eisai Co Ltd Policristais de donepezil e processo para a sua producao
US6109269A (en) 1999-04-30 2000-08-29 Medtronic, Inc. Method of treating addiction by brain infusion
US6497631B1 (en) 1999-09-15 2002-12-24 Wilson Sporting Goods Co. Ball bat
US6372919B1 (en) 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
US6569887B2 (en) 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US20040127541A1 (en) 2002-07-31 2004-07-01 Janet Codd Bicifadine formulation
RU2005117630A (ru) 2002-11-08 2006-01-20 Дов Фармасьютикал, Инк. (Us) Полиморфы гидрохлорида бицифадина

Also Published As

Publication number Publication date
US20040157869A1 (en) 2004-08-12
HUP0401515A2 (hu) 2004-12-28
EP1427411A4 (en) 2005-04-20
BR0212147A (pt) 2004-08-24
US20040157908A1 (en) 2004-08-12
DE60218703T2 (de) 2007-12-06
MXPA04001643A (es) 2004-05-31
NZ531606A (en) 2005-08-26
RU2300522C2 (ru) 2007-06-10
DE60218703D1 (de) 2007-04-19
WO2003017927A3 (en) 2003-04-17
US6569887B2 (en) 2003-05-27
NO20040794L (no) 2004-05-17
US20030181508A1 (en) 2003-09-25
EP1427411A2 (en) 2004-06-16
JP2005504049A (ja) 2005-02-10
CN1575170A (zh) 2005-02-02
CN101050199A (zh) 2007-10-10
US20030045567A1 (en) 2003-03-06
KR20040065549A (ko) 2004-07-22
US20040157870A1 (en) 2004-08-12
US7098230B2 (en) 2006-08-29
US6716868B2 (en) 2004-04-06
CA2458217A1 (en) 2003-03-06
WO2003017927A2 (en) 2003-03-06
PL368601A1 (en) 2005-04-04
US7041835B2 (en) 2006-05-09
ATE355838T1 (de) 2007-03-15
IL160545A0 (en) 2004-07-25
US7081471B2 (en) 2006-07-25
ES2284968T3 (es) 2007-11-16
PT1427411E (pt) 2007-06-15
NO327424B1 (no) 2009-06-29
EP1427411B1 (en) 2007-03-07
RU2004108694A (ru) 2005-03-10
ZA200401545B (en) 2005-03-10
US20070082938A1 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
DK1427411T3 (da) -(-)-1-(3,4-dichlorphenyl)-3-azabicyclo[3.1.0]hexan, præparater deraf og anvendelser som dopamingenoptagelsesinhibitor
AP1830A (en) Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same.
TNSN07235A1 (en) Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
MXPA04001452A (es) Cristales anhidros que incluyen una sal del acido malonico de una 2-indolinona sustituida con 3-prrol, metodos de preparacion y composiciones que los contienen.
HK1155146A1 (zh) 作為藥物活性劑的茚衍生物
DK1506185T3 (da) Forbindelser og deres anvendelse som 5-HT-inhibitorer
MXPA05007341A (es) Derivados de 2-piperidona como agonistas de prostaglandina.
IL171992A0 (en) Storage-stable fluorescent whitener formulations
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
MXPA04001968A (es) Agentes antidiabeticos.
PT2049480E (pt) Derivados de 2-arilindole como inibidores da mpges-i
MXPA05011176A (es) Derivados de carboxamida como agentes antidiabeticos.
AP1766A (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation.
NO20071372L (no) Nye polymorfer av azabisykloheksan
WO2004108086A3 (en) HYDANTOIN DERIVATIVES AS INHIBITORS OF TUMOR NECROSIS FACTOR-α CONVERTING ENZYME (TACE)
MY138826A (en) 2,7-substituted indoles
TW200508195A (en) 3-aminopyrrolidines as inhibitors of monoamine uptake
HK1075663A1 (en) Novel heteroaryl-substituted acetone derivatives as inhibitors of phospholipase a sb 2 /sb
IL153784A0 (en) Novel n-(2-phenyl-3-aminopropyl) naphthamides
DK1335922T3 (da) Fremgangsmåde til fremstilling af 4'-demethyl-4'-O-substituerede 1-deoxypodophyllotoxinderivater og geometriske isomerer deraf og anticancersammensætninger, der indeholder samme
AU2002359985A1 (en) Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor
AU2003256091A1 (en) 1,2,4-triazole derivative, method for preparing the same, and pharmaceutical composition containing the same
AU2002326391A1 (en) Carvedilol polymorph
DE60235119D1 (en) Bipyridinylderivate als hochselektive cyclooxygenase-2-inhibitoren
SG145572A1 (en) Intermediates useful in the synthesis of hiv-protease inhibitors and methods for preparing the same